<DOC>
	<DOCNO>NCT01988272</DOCNO>
	<brief_summary>The goal study develop image base method accurately determine energy absorb ( absorb dose ) tumor tissue bone marrow radioimmunotherapy I-131 tositumomab . The administration radioactive , iodine-131 label , monoclonal antibody I-131 tositumomab , ( also know Bexxar ) part patient 's clinical treatment protocol . For absorbed dose measurement , investigator University Michigan evaluate new Nuclear Medicine SPECT/CT image system . This new camera combine CT image system addition Nuclear Medicine SPECT scanner . CT scan allow doctor see high quality picture internal organ . The Nuclear Medicine SPECT scanner allow doctor see uptake radioactive I-131 include tumor site . The improved imaging use SPECT/CT enables accurate calculation energy absorb tumor tissue bone marrow . Using result calculation clinical follow data , researcher investigate relationship absorb dose tumor patient 's tumor response well relationship absorb dose bone marrow bone marrow toxicity . These relationship potentially used future doctor help determine much radioactive I-131 administer patient get optimal result .</brief_summary>
	<brief_title>Imaging Based Dosimetry Individualized Internal Emitter Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>• Clinically stable patient undergo I131 Tositumomab ( Bexxar ) treatment NonHodgkin Lymphomas • Clinical instability Patients unable lie flat image system long enough permit image protocol perform Refusal provide informed consent Patients pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>SPECT/CT</keyword>
	<keyword>Dosimetry</keyword>
	<keyword>Radiation absorb dose</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>I-131 tositumomab radioimmunotherapy</keyword>
</DOC>